Bryn Mawr Trust Advisors LLC Makes New $484,000 Investment in Quest Diagnostics Incorporated $DGX

Bryn Mawr Trust Advisors LLC bought a new position in Quest Diagnostics Incorporated (NYSE:DGX) during the second quarter, Holdings Channel.com reports. The firm bought 2,283 shares of the medical research company’s stock, valued at approximately $484,000.

Several other institutional investors also recently modified their holdings of DGX. Key Financial Inc boosted its position in Quest Diagnostics by 1,728.6% in the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares during the last quarter. Quattro Advisors LLC purchased a new stake in shares of Quest Diagnostics during the 4th quarter valued at $25,000. DV Equities LLC purchased a new stake in shares of Quest Diagnostics during the 4th quarter valued at $27,000. Sittner & Nelson LLC bought a new stake in shares of Quest Diagnostics during the 4th quarter worth $29,000. Finally, McIlrath & Eck LLC bought a new stake in shares of Quest Diagnostics during the 4th quarter worth $32,000. 88.06% of the stock is owned by institutional investors.

Trending Headlines about Quest Diagnostics

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Broad-based earnings estimate increases: Zacks Research raised its FY2026 EPS forecast to $11.15 from $10.66, FY2027 to $11.71 from $11.50, and FY2028 to $12.90 from $12.50. The firm also increased estimates for Q3 and Q4 2026, Q1 through Q3 2027, and Q1 and Q2 2028. These revisions suggest improving expectations for Quest Diagnostics’ earnings growth. MarketBeat analyst estimate updates
• Positive Sentiment: Momentum remains favorable: A Zacks analysis highlighted DGX’s 2.29% weekly gain and evaluated whether the stock can continue to attract momentum investors. The coverage may reinforce positive sentiment following the recent advance. Quest Diagnostics Is Up 2.29% in One Week
• Positive Sentiment: Dividend support: Quest Diagnostics declared a quarterly dividend of $0.86 per share, payable October 21 to shareholders of record October 6. The annualized yield is approximately 1.5%, providing ongoing shareholder income. Quest Diagnostics dividend announcement
• Neutral Sentiment: One estimate was lowered: Zacks reduced its Q4 2027 EPS forecast to $2.90 from $3.05, partially offsetting the otherwise positive revisions. The firm’s full-year 2027 and 2028 forecasts nevertheless remain higher than its previous estimates.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $234.48 on Friday. The stock has a market capitalization of $25.88 billion, a P/E ratio of 24.89, a PEG ratio of 2.18 and a beta of 0.56. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. The firm’s 50 day moving average is $215.60 and its 200 day moving average is $203.18. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $240.13.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period last year, the firm earned $2.62 EPS. Quest Diagnostics’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be given a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. Quest Diagnostics’s payout ratio is 36.52%.

Insider Activity

In related news, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer directly owned 132,423 shares in the company, valued at approximately $25,708,601.22. The trade was a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. This trade represents a 37.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 19,747 shares of company stock worth $3,947,088. 0.88% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Evercore set a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Robert W. Baird lifted their price objective on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. JPMorgan Chase & Co. boosted their target price on shares of Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research note on Tuesday, July 28th. Truist Financial increased their target price on shares of Quest Diagnostics from $225.00 to $250.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group restated a “buy” rating and set a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $235.31.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.